CLARENCE VASTINE: Open Payments
NPI 1902121379 · GOODYEAR, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,275 in 70 payments from 17 companies in 2025. Trend: 2023 $1,162 · 2024 $1,156 · 2025 $1,275
Food & beverage: $1,275
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $221 |
| GlaxoSmithKline, LLC. | 11 | $173 |
| Novo Nordisk Inc | 14 | $162 |
| ABBVIE INC. | 10 | $152 |
| Lilly USA, LLC | 10 | $136 |
| Corcept Therapeutics | 3 | $75 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $66 |
| Astellas Pharma US Inc | 2 | $63 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $60 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $29 |
Products named: AIRSUPRA, TRELEGY ELLIPTA, UBRELVY, MOUNJARO, Ozempic, Korlym, Kerendia, Veozah.
Industry payments across AZ — which companies pay providers there.
